On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

A proposed Arkansas law would forbid pharmacy benefit managers (PBMs) from holding or acquiring interest in retail pharmacy ...

Traveling over our heads at hypersonic speeds beyond Mach 7, lies the future of spy plane technology. It can be anywhere in ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...